DAX+1,11 % EUR/USD-0,52 % Gold-0,45 % Öl (Brent)+0,87 %

Diskussion zu Cann Trust Holdings


WKN: A2DWH4 | Symbol: TRST
4,360
16:05:10
Stuttgart
+1,63 %
+0,070 EUR

Beitrag schreiben

Begriffe und/oder Benutzer

 

https://www.stockhouse.com/news/press-releases/2017/10/17/canntrust-reports-record-revenue-and-patient-growth-for-the-current-quarter
News zu CannTrust
http://www.stockhouse.com/news/press-releases/2017/11/01/canntrust-announces-upsize-of-previously-announced-bought-deal-private
CannTrust beliefert Australien und Deutschland
VAUGHAN, ON, Nov. 8, 2017 /CNW/ - CannTrust Holdings Inc. ("CannTrust" or the "Company" I CSE: TRST), a licensed producer of medical cannabis under the Health Canada Access to Cannabis for Medical Purposes Regulation (" ACMPR ") program, is pleased to announce that it has received Health Canada approval to export medical marijuana internationally to Countries where medical marijuana is legalized and that the Company has now begun shipping to Australia.

"We are very proud and excited to begin the international shipping of our pharmaceutically standardized medical marijuana products. Australia is the first of many markets that we are expecting to supply. Other countries that we anticipate shipping to shortly are Germany, Denmark and Brazil", said Brad Rogers, President of CannTrust Inc.

Rogers continued "Germany has implemented one of the most progressive medical marijuana Plans whereby marijuana will be distributed via Pharmacies with Insurers required to cover the costs just as they do for Pharmaceutical drugs. CannTrust is an experienced and advanced Licensed Producer of Pharmaceutical grade cannabis in Canada and our recently completed Phase 1 of our 430,000 square feet Niagara Facility, is perfectly timed in order for us to supply the orders we have received. The pending legislation to legalize the adult consumer recreational use of cannabis provides a further major opportunity for the Company. With the completion of all phases of our Niagara expansion we plan to have in excess of 1,000,000 square feet of production capacity. This will give us the ability to acquire a substantial share of the increased demand arising from these new markets."

Company CEO Eric Paul, a veteran Pharmacist, said "Our plan was always to be a Pharmaceutical Company producing quality medical cannabis in a variety of unique dosage forms that will provide the best treatment options for patients. Our shipments to Australia are just the beginning of what we believe will be a World market opportunity for us along with our exclusive global pharma manufacturing partner, Apotex Inc., for our Canadian made, pharmaceutically standardized, cannabis products."


Beitrag zu dieser Diskussion schreiben